logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer – first line

< Back

Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer – first line

Drugs

Cancer and Palliative Care

November 2012


Enobosarm (Ostarine) is intended to be used as first line therapy for the treatment of cachexia in patients with advanced non-small cell lung cancer (NSCLC) in combination with first line chemotherapy. If licensed, it would represent the first in a new class of drug for this patient group. Enobosarm is an oral, non-steroidal selective androgen receptor modulator (SARM).
NSCLC accounts for approximately 80% of all lung cancers. Cachexia is common in patients with NSCLC and approximately 50% of patients with advanced NSCLC have severe muscle loss. Cachexia impairs quality of life and response to therapy, increasing the morbidity and mortality of cancer patients.
The treatment approach for cachexia is multimodal and includes treatment of causes for decreased nutritional intake, evaluation of anti-neoplastic options to reduce the catabolic drive of cancer, nutritional therapy, use of corticosteroids and progestational agents, and non-drug treatment like nutritional counselling and physical training. Enobosarm is currently in two phase III clinical trials comparing its effect on physical function and lean body mass against placebo. This trial is expected to complete in second half of 2013.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts